Core Insights - Cardinal Health reported better-than-expected first-quarter profit and sales, driven by growing demand from existing customers [1] - Despite a revenue decline in its largest division, Pharmaceutical & Specialty Solutions, the company indicated that revenue would have increased by 16% year-over-year without the loss of a significant contract [1] - The company raised its full-year EPS guidance, and its shares reached a new all-time intraday high [1] Financial Performance - The company reported fiscal 2025 first-quarter adjusted earnings per share (EPS) of 1.88,exceedinganalystforecasts[1]−Revenuedecreasedby452.28 billion, but still surpassed consensus estimates [1] - Sales in the Pharmaceutical and Specialty Solutions unit fell by 5% to 48.0billionduetotheexpirationofadistributioncontractwithOptumRx;however,excludingthisimpact,revenuewouldhaveincreasedby163.1 billion, attributed to higher volumes from existing customers [1] - Other revenue surged by 13% to 1.2billion,drivenby"at−HomeSolutions,NuclearandPrecisionHealthSolutions,andOptiFreightLogistics"[1]FutureOutlook−CardinalHealthnowprojectsfull−yearEPSintherangeof7.75 to 7.90,anincreasefromthepreviousguidanceof7.55 to 7.70[1]−Followingtheearningsreport,sharesofCardinalHealthincreasednearly7115.76, with an earlier peak of $119.12 [1]